高脂血症患者与正常人口服甲硝唑药代动力学对比研究  

COMPARISION OF PHARMACOKINETICS IN METRONIDAZOLE BETWEEN HEALTHY VOLUNTERS AND PATIENTS WITH HYPERLIPIDEMIA

作　　者：焦效兰[1,2,3] 杨毓章[1,2,3] 爱民 王宏智[1,2,3] 周建秀 郭秀兰 肖跃平[1,2,3] 

机构地区：[1]内蒙古医学院药理教研室 [2]内蒙古电力学校医务室 [3]内蒙古医学院第一附院

出　　处：《中国临床药理学杂志》1998年第2期109-112,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：本文对９名高脂血症患者及９名健康志愿者进行了单剂量口服甲硝唑６００ｍｇ的唾液药代动力学对比研究，以探讨高脂血症患者服用甲硝唑后ＡＤＲｓ出现率高的原因；结果为：两组甲硝唑药时曲线均符合一室开放模型。结果为高血脂组：Ｔｐ为１．１５±１．２０ｈ；Ｃｍａｘ为１４．０２±１．５４ｍｇ·Ｌ－１；Ｔ１／２ｋｅ为１２．９１±６．３０ｈ；ＡＵＣ为２７２．２４±８２．８５μｇ·ｈ·Ｌ－１。正常组：Ｔｐ为２．２０４±１．５３ｈ；Ｃｍａｘ为１０．３５±２．７７ｍｇ·Ｌ－１；Ｔ１／２Ｋｅ为８．０７±４．２８ｈ；ＡＵＣ为１５４．４３±６９．４１μｇ·ｈ·Ｌ－１。两组之间Ｔ检验差异显著，高脂血症者对甲硝唑吸收快、达峰快、吸收量多、代谢排泄慢、Ｔ１／２延长、ＡＵＣ明显增大造成体内药物浓度高。结果表明临床高脂血症患者用甲硝唑后的药物不良反应多且严重的原因。In order to investigate why the rates of incidence of ADRs of metronidazole(MTZ) in patients with hyperlipidemia were higher than in health, the pharmacokinetics of MTZ were studied in two groups subjects (health and patient) by single oral dose of 600 mg of MTZ tablets.The parameters were Cmax:10.35±2.77 mg·L-1 and 14.02±1.54 mg·L-1;Tpeak:2.20±1.54 h and 1.16± 1.2 h;T1/2 Ke 8.07±4.28 h and 12.91±6.30 h;AUC:154.43±69.41 mg·h·L-1 and 272.24±82.85 mg·h·L-1 for health and patients respectively,T-test indicated that there were significant difference between them (P<0.05). The results indicated that patients with hyperlipidemia absorbed MTZ rapidly and excessively; but metabolism and elimination of MTZ were slowly. So,the AUC of MTZ remarkable increase than health's,that may be the one of the reasons.

关 键 词：高脂血症 甲硝唑 高效液相色谱法 药代动力学 药物不良反应 

分 类 号：R589.2[医药卫生—内分泌] R978.61[医药卫生—内科学]